Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Biomaterials ; 275: 120966, 2021 08.
Article in English | MEDLINE | ID: mdl-34147715

ABSTRACT

Non-viral vectors offer the potential to deliver nucleic acids including mRNA and DNA into cells in vivo. However, designing materials that effectively deliver to target organs and then to desired compartments within the cell remains a challenge. Here we develop polymeric materials that can be optimized for either DNA transcription in the nucleus or mRNA translation in the cytosol. We synthesized poly(beta amino ester) terpolymers (PBAEs) with modular changes to monomer chemistry to investigate influence on nucleic acid delivery. We identified two PBAEs with a single monomer change as being effective for either DNA (D-90-C12-103) or mRNA (DD-90-C12-103) delivery to lung endothelium following intravenous injection in mice. Physical properties such as particle size or charge did not account for the difference in transfection efficacy. However, endosome co-localization studies revealed that D-90-C12-103 nanoparticles resided in late endosomes to a greater extent than DD-90-C12-103. We compared luciferase expression in vivo and observed that, even with nucleic acid optimized vectors, peak luminescence using mRNA was two orders of magnitude greater than pDNA in the lungs of mice following systemic delivery. This study indicates that different nucleic acids require tailored delivery vectors, and further support the potential of PBAEs as intracellular delivery materials.


Subject(s)
Nanoparticles , Polymers , Animals , DNA , Lipids , Lung , Mice , RNA, Messenger/genetics , Transfection
2.
Adv Mater ; 31(8): e1805116, 2019 Feb.
Article in English | MEDLINE | ID: mdl-30609147

ABSTRACT

Noninvasive aerosol inhalation is an established method of drug delivery to the lung, and remains a desirable route for nucleic-acid-based therapeutics. In vitro transcribed (IVT) mRNA has broad therapeutic applicability as it permits temporal and dose-dependent control of encoded protein expression. Inhaled delivery of IVT-mRNA has not yet been demonstrated and requires development of safe and effective materials. To meet this need, hyperbranched poly(beta amino esters) (hPBAEs) are synthesized to enable nanoformulation of stable and concentrated polyplexes suitable for inhalation. This strategy achieves uniform distribution of luciferase mRNA throughout all five lobes of the lung and produces 101.2 ng g-1 of luciferase protein 24 h after inhalation of hPBAE polyplexes. Importantly, delivery is localized to the lung, and no luminescence is observed in other tissues. Furthermore, using an Ai14 reporter mouse model it is identified that 24.6% of the total lung epithelial cell population is transfected after a single dose. Repeat dosing of inhaled hPBAE-mRNA generates consistent protein production in the lung, without local or systemic toxicity. The results indicate that nebulized delivery of IVT-mRNA facilitated by hPBAE vectors may provide a clinically relevant delivery system to lung epithelium.


Subject(s)
Epithelial Cells/metabolism , Luciferases/genetics , Nanoparticles/chemistry , Polymers/chemistry , RNA, Messenger/chemistry , Administration, Inhalation , Animals , Drug Compounding/methods , Drug Liberation , Epithelial Cells/cytology , Female , Gene Transfer Techniques , Genetic Therapy/methods , Hydrogen-Ion Concentration , Lung/drug effects , Mice , Mice, Inbred C57BL , Models, Animal , RNA, Messenger/administration & dosage , RNA, Messenger/adverse effects , RNA, Messenger/metabolism , Tissue Distribution , Transfection/methods
3.
Nano Lett ; 18(10): 6449-6454, 2018 10 10.
Article in English | MEDLINE | ID: mdl-30211557

ABSTRACT

mRNA therapeutics hold great potential for treating a variety of diseases through protein-replacement, immunomodulation, and gene editing. However, much like siRNA therapy the majority of progress in mRNA delivery has been confined to the liver. Previously, we demonstrated that poly(ß-amino esters), a class of degradable polymers, are capable of systemic mRNA delivery to the lungs in mice when formulated into nanoparticles with poly(ethylene glycol)-lipid conjugates. Using experimental design, a statistical approach to optimization that reduces experimental burden, we demonstrate herein that these degradable polymer-lipid nanoparticles can be optimized in terms of polymer synthesis and nanoparticle formulation to achieve a multiple order-of-magnitude increase in potency. Furthermore, using genetically engineered Cre reporter mice, we demonstrate that mRNA is functionally delivered to both the lung endothelium and pulmonary immune cells, expanding the potential utility of these nanoparticles.


Subject(s)
Endothelium/drug effects , Lung/drug effects , Nanoparticles/administration & dosage , RNA, Small Interfering/administration & dosage , Animals , Endothelium/immunology , Endothelium/pathology , Gene Transfer Techniques , Humans , Lipids/administration & dosage , Lipids/chemistry , Lung/immunology , Lung/pathology , Mice , Nanoparticles/chemistry , Polyethylene Glycols/chemistry , Polymers/chemistry , RNA, Messenger/chemistry , RNA, Messenger/genetics , RNA, Small Interfering/chemistry , RNA, Small Interfering/genetics
4.
Angew Chem Int Ed Engl ; 57(41): 13582-13586, 2018 10 08.
Article in English | MEDLINE | ID: mdl-30112821

ABSTRACT

RNAs are a promising class of therapeutics given their ability to regulate protein concentrations at the cellular level. Developing safe and effective strategies to deliver RNAs remains important for realizing their full clinical potential. Here, we develop lipid nanoparticle formulations that can deliver short interfering RNAs (for gene silencing) or messenger RNAs (for gene upregulation). Specifically, we study how the tail length, tail geometry, and linker spacing in diketopiperazine lipid materials influences LNP potency with siRNAs and mRNAs. Eight lipid materials are synthesized, and 16 total formulations are screened for activity in vitro; the lead material is evaluated with mRNA for in vivo use and demonstrates luciferase protein expression in the spleen. In undertaking this approach, not only do we develop synthetic routes to delivery materials, but we also reveal structural criteria that could be useful for developing next-generation delivery materials for RNA therapeutics.


Subject(s)
Lipids/chemistry , Nanoparticles/chemistry , RNA, Messenger/administration & dosage , RNA, Small Interfering/administration & dosage
5.
Adv Healthc Mater ; 7(14): e1800249, 2018 07.
Article in English | MEDLINE | ID: mdl-29761648

ABSTRACT

The production of new proteins with messenger RNA (mRNA) has gained a broad interest due to its potential for addressing a wide range of diseases. Here, the design and characterization of novel ionizable poly(ß-amino ester)-co-poly(caprolactone) terpolymers, synthesized via the combination of the ring opening polymerization and the Michael step-growth polymerization, are reported. The versatility of this method is demonstrated by varying the number of caprolactone units attached to each poly(ß-amino ester) (PBAE) terpolymer. The ability of the novel poly-caprolactone (PCL)-based PBAE materials to deliver mRNA is shown to depend on the physiochemical characteristics of the material, such as lipophilicity, as well as the formulation method used to complex the polymer with the oligonucleotide. This latter variable represents a previously unstudied aspect of PBAE library screens that can play an important role in identifying true top candidates for nucleic acid delivery. The most stable terpolymer is injected intravenously (IV) in mice and shows a transfection efficacy several times higher than the polyethylenimine (PEI) which is focused in the spleen, opening the possibility to use these biodegradable carriers in the intravenous delivery of antigen-encoding mRNA for cancer immunotherapy and vaccination.


Subject(s)
Genetic Vectors/chemistry , Polyesters/chemistry , Polymers/chemistry , RNA, Messenger/chemistry , Cell Survival/physiology , HeLa Cells , Humans , Nanoparticles/chemistry , Polyethyleneimine/chemistry
6.
Mol Ther Nucleic Acids ; 10: 55-63, 2018 Mar 02.
Article in English | MEDLINE | ID: mdl-29499956

ABSTRACT

mRNA therapeutics hold promise for the treatment of diseases requiring intracellular protein expression and for use in genome editing systems, but mRNA must transfect the desired tissue and cell type to be efficacious. Nanoparticle vectors that deliver the mRNA are often evaluated using mRNA encoding for reporter genes such as firefly luciferase (FLuc); however, single-cell resolution of mRNA expression cannot generally be achieved with FLuc, and, thus, the transfected cell populations cannot be determined without additional steps or experiments. To more rapidly identify which types of cells an mRNA formulation transfects in vivo, we describe a Cre recombinase (Cre)-based system that permanently expresses fluorescent tdTomato protein in transfected cells of genetically modified mice. Following in vivo application of vectored Cre mRNA, it is possible to visualize successfully transfected cells via Cre-mediated tdTomato expression in bulk tissues and with single-cell resolution. Using this system, we identify previously unknown transfected cell types of an existing mRNA delivery vehicle in vivo and also develop a new mRNA formulation capable of transfecting lung endothelial cells. Importantly, the same formulations with mRNA encoding for fluorescent protein delivered to wild-type mice did not produce sufficient signal for any visualization in vivo, demonstrating the significantly improved sensitivity of our Cre-based system. We believe that the system described here may facilitate the identification and characterization of mRNA delivery vectors to new tissues and cell types.

7.
Adv Mater ; 29(33)2017 Sep.
Article in English | MEDLINE | ID: mdl-28681930

ABSTRACT

B lymphocytes regulate several aspects of immunity including antibody production, cytokine secretion, and T-cell activation; moreover, B cell misregulation is implicated in autoimmune disorders and cancers such as multiple sclerosis and non-Hodgkin's lymphomas. The delivery of messenger RNA (mRNA) into B cells can be used to modulate and study these biological functions by means of inducing functional protein expression in a dose-dependent and time-controlled manner. However, current in vivo mRNA delivery systems fail to transfect B lymphocytes and instead primarily target hepatocytes and dendritic cells. Here, the design, synthesis, and biological evaluation of a lipid nanoparticle (LNP) system that can encapsulate mRNA, navigate to the spleen, transfect B lymphocytes, and induce more than 60 pg of protein expression per million B cells within the spleen is described. Importantly, this LNP induces more than 85% of total protein production in the spleen, despite LNPs being observed transiently in the liver and other organs. These results demonstrate that LNP composition alone can be used to modulate the site of protein induction in vivo, highlighting the critical importance of designing and synthesizing new nanomaterials for nucleic acid delivery.


Subject(s)
Lipids/chemistry , B-Lymphocytes , Liver , Nanoparticles , RNA, Messenger
8.
Genome Med ; 9(1): 60, 2017 06 27.
Article in English | MEDLINE | ID: mdl-28655327

ABSTRACT

The rapid expansion of the available genomic data continues to greatly impact biomedical science and medicine. Fulfilling the clinical potential of genetic discoveries requires the development of therapeutics that can specifically modulate the expression of disease-relevant genes. RNA-based drugs, including short interfering RNAs and antisense oligonucleotides, are particularly promising examples of this newer class of biologics. For over two decades, researchers have been trying to overcome major challenges for utilizing such RNAs in a therapeutic context, including intracellular delivery, stability, and immune response activation. This research is finally beginning to bear fruit as the first RNA drugs gain FDA approval and more advance to the final phases of clinical trials. Furthermore, the recent advent of CRISPR, an RNA-guided gene-editing technology, as well as new strides in the delivery of messenger RNA transcribed in vitro, have triggered a major expansion of the RNA-therapeutics field. In this review, we discuss the challenges for clinical translation of RNA-based therapeutics, with an emphasis on recent advances in delivery technologies, and present an overview of the applications of RNA-based drugs for modulation of gene/protein expression and genome editing that are currently being investigated both in the laboratory as well as in the clinic.


Subject(s)
Gene Editing , Genetic Therapy/methods , Oligonucleotides, Antisense/therapeutic use , RNA, Small Interfering/therapeutic use , Humans
9.
Angew Chem Int Ed Engl ; 55(44): 13808-13812, 2016 10 24.
Article in English | MEDLINE | ID: mdl-27690187

ABSTRACT

Therapeutic nucleic acids hold great promise for the treatment of disease but require vectors for safe and effective delivery. Synthetic nanoparticle vectors composed of poly(ß-amino esters) (PBAEs) and nucleic acids have previously demonstrated potential utility for local delivery applications. To expand this potential utility to include systemic delivery of mRNA, hybrid polymer-lipid nanoformulations for systemic delivery to the lungs were developed. Through coformulation of PBAEs with lipid-polyethylene glycol (PEG), mRNA formulations were developed with increased serum stability and increased in vitro potency. The formulations were capable of functional delivery of mRNA to the lungs after intravenous administration in mice. To our knowledge, this is the first report of the systemic administration of mRNA for delivery to the lungs using degradable polymer-lipid nanoparticles.


Subject(s)
Lipids/chemistry , Lung/chemistry , Nanoparticles/chemistry , Polymers/chemistry , RNA, Messenger/chemistry , Administration, Intravenous , Animals , Mice , Molecular Structure , Particle Size , Polymers/administration & dosage , RNA, Messenger/administration & dosage , RNA, Messenger/chemical synthesis , Surface Properties
10.
Biomaterials ; 109: 78-87, 2016 12.
Article in English | MEDLINE | ID: mdl-27680591

ABSTRACT

mRNA has broad potential for treating diseases requiring protein expression. However, mRNA can also induce an immune response with associated toxicity. Replacement of uridine bases with pseudouridine has been postulated to modulate both mRNA immunogenicity and potency. Here, we explore the immune response and activity of lipid nanoparticle-formulated unmodified and pseudouridine-modified mRNAs administered systemically in vivo. Pseudouridine modification to mRNA had no significant effect on lipid nanoparticle physical properties, protein expression in vivo, or mRNA immunogenicity compared to unmodified mRNA when delivered systemically with liver-targeting lipid nanoparticles, but reduced in vitro transfection levels. Indicators of a transient, extracellular innate immune response to mRNA were observed, including neutrophilia, myeloid cell activation, and up-regulation of four serum cytokines. This study provides insight into the immune responses to mRNA lipid nanoparticles, and suggests that pseudouridine modifications may be unnecessary for therapeutic application of mRNA in the liver.


Subject(s)
Lipids/chemistry , Nanoparticles/chemistry , Pseudouridine/chemistry , RNA, Messenger/chemistry , Animals , Cytokines/metabolism , Female , Gene Expression , Gene Transfer Techniques , HeLa Cells , Humans , Immunity, Innate , Liver/metabolism , Mice, Inbred C57BL , Myeloid Cells/immunology , Nanoparticles/administration & dosage , Particle Size , RNA, Messenger/administration & dosage , RNA, Messenger/biosynthesis , RNA, Messenger/immunology , Surface Properties , Transfection
11.
Cancer Treat Res ; 166: 293-322, 2015.
Article in English | MEDLINE | ID: mdl-25895874

ABSTRACT

To be legally sold in the United States, all drugs must go through the FDA approval process. This chapter introduces the FDA approval process and describes the clinical trials required for a drug to gain approval. We then look at the different cancer nanotherapeutics and in vivo diagnostics that are currently in clinical trials or have already received approval. These nanotechnologies are catagorized and described based on the delivery vehicle: liposomes, polymer micelles, albumin-bound chemotherapeutics, polymer-bound chemotherapeutics, and inorganic particles.


Subject(s)
Clinical Trials as Topic/legislation & jurisprudence , Drug Approval/legislation & jurisprudence , Nanomedicine/legislation & jurisprudence , Neoplasms/drug therapy , Humans , Nanomedicine/methods , United States , United States Food and Drug Administration
12.
J Biomater Sci Polym Ed ; 25(1): 88-100, 2014.
Article in English | MEDLINE | ID: mdl-24070140

ABSTRACT

PURPOSE: To alter the composition and structure of silicone hydrogel contact lenses to achieve controlled release of dexamethasone and evaluate the lens optical and mechanical properties compared to commercial lenses. There is a tremendous need for controlled release of drugs from ocular biomaterials as the majority of ophthalmic drugs are delivered via topical eye drops, which have low bioavailability and patient compliance. METHODS: Poly(PDMS-co-TRIS-co-DMA) contact lenses were synthesized with varying PDMS/TRIS:DMA ratios (0.25:1, 0.67:1, 1.5:1) as well as with additional crosslinking monomers. Lenses were characterized via in vitro release studies in a microfluidic device at ocular flowrates and in large well-mixed volumes, optical quality studies over visible wavelengths, mechanical analysis, and determination of polymer volume fraction in the swollen state. RESULTS: Extended and controlled release of therapeutically relevant concentrations of dexamethasone was achieved for multiple day, continuous wear up to 60 days at in vitro ocular flowrates. Release was delayed due to a combination of increased hydrophobic to hydrophilic composition and the inclusion of additional structural constraints, both of which decreased the polymer volume fraction in the swollen state. However, decreased mass release rates were at the expense of increased modulus and decreased lens flexibility. All lenses had high optical clarity (∼90% transmittance) and contained highly oxygen permeable siloxane composition similar to those found in commercial silicone hydrogel lenses, but they had poor flexibility for use as soft contact lenses. CONCLUSIONS: Based on our results, the lenses described herein likely have too high of a modulus for use as extended-wear, soft contact lenses with drug release. Therefore, other controlled release methods would be better suited for maintaining adequate mechanical properties and achieving controlled and extended release for the duration of wear in soft, silicone hydrogel contact lens biomaterials. However, these biomaterials may find clinical use as more rigid gas permeable contact lenses or inserts.


Subject(s)
Biocompatible Materials/chemistry , Contact Lenses, Extended-Wear , Dexamethasone/chemistry , Drug Carriers/chemistry , Hydrogels/chemistry , Silicones/chemistry , Delayed-Action Preparations , Dexamethasone/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...